The ORR of oral single-agent regimens in the first-line treatment of metastatic HER2-negative BC has been reported to be 11%–31%21–24 and to reach 50%–60% when these regimens are combined with agents such as capecitabine25–29. The gene discussed is ERBB2; the disease is breast cancer.